FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)
Prostate CA
Prostate Cancers
Prostate Cancer (Post Prostatectomy)
Prostate Cancer
Prostate Cancer Patients Undergoing Radical Prostatectomy
High-risk Prostate Cancer

Interventions

BIOLOGICAL: FK-PC101
BIOLOGICAL: Standard of Care (SOC)

Sponsor

Cellvax Therapeutics Inc